Brincidofovir

Drug Profile

Brincidofovir

Alternative Names: BCV; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Centers for Disease Control and Prevention; Chimerix; National Institutes of Health (USA); University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections; Adenovirus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adenovirus infections; Cytomegalovirus infections; Smallpox
  • Phase II/III Viral infections
  • Research Monkeypox
  • No development reported Human polyomavirus infections
  • Discontinued Ebola virus infections

Most Recent Events

  • 09 May 2017 Final adverse events data from a phase I trial in Cytomegalovirus infections (In volunteers) released by Chimerix (IV)
  • 09 May 2017 Chimerix plans the AdAPT trial (Study 999) for Adenovirus infections in Europe and USA (PO)
  • 09 May 2017 Chimerix plans the MVP-Peds trial of brincidofovir for Viral infections (In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top